Have questions about Haute MD?

    Schedule a quick call with our membership team. No obligation.

    Full refund if not approved · Benefits activate day one

    Longevity Medicine

    What Is NAD Therapy?

    Last reviewed: May 2026 · Haute MD Editorial Team

    NAD+ is a coenzyme essential for energy production, DNA repair, and activation of sirtuins linked to longevity. NAD+ levels decline approximately 50% between ages 40-60. Administration methods include IV infusion, subcutaneous injection, oral precursors (NMN, NR), and nasal spray.

    Why NAD+ matters

    NAD+ is required for mitochondrial energy production, DNA repair, sirtuin activation, and hundreds of metabolic reactions. Declining NAD+ levels are implicated in many hallmarks of aging including mitochondrial dysfunction and impaired DNA repair.

    How NAD+ is administered

    IV infusions (typically 500-1000 mg over 1-4 hours) deliver the highest doses. Subcutaneous injections and oral precursors (NMN, NR) provide more practical ongoing support.

    Frequently Asked Questions

    Is NAD+ therapy proven?

    Animal studies and early human research are promising. Larger randomized human trials are ongoing. NMN and NR are well-tolerated and reliably raise NAD+ levels.

    How often is NAD+ therapy administered?

    Protocols vary. Initial IV protocols may be daily for a week followed by maintenance every 2-4 weeks. Oral precursors are taken daily.

    Are there side effects?

    IV NAD+ can cause chest pressure, nausea, or flushing during infusion if administered too quickly. Oral precursors are generally well-tolerated.

    Get Help Now

    Speak with a Haute MD Longevity Medicine physician

    Are you a Longevity Medicine physician?

    Join Haute MD Network and have your profile featured alongside these answers.

    Apply for the Network

    Related Guides

    Are you a longevity medicine physician?

    Join Haute MD Network and have your profile featured alongside these answers — published on HauteLiving.com, a verified Google News publisher since 2005.

    Apply for the Network